ZYME

ZYME

USD

Zymeworks Inc. Common Stock

$18.160-0.230 (-1.251%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$18.390

Máximo

$18.770

Mínimo

$18.000

Volume

0.08M

Fundamentos da empresa

Capitalização de mercado

1.4B

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.66M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $9.03Atual $18.160Máximo $19.98

Notícias relacionadas

GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the

Ver mais
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall

Ver mais
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Analyst Upgrades

HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26

HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks from Neutral to Buy and raises the price target from $13 to $26.

Ver mais
HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26
GlobeNewswire

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung

Ver mais
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Analyst Upgrades

B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30

B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks with a Buy rating and announces Price Target of $30.

Ver mais
B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30
GlobeNewswire

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.